Correlation Between Amylyx Pharmaceuticals and Dermata Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Amylyx Pharmaceuticals and Dermata Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Amylyx Pharmaceuticals and Dermata Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Amylyx Pharmaceuticals and Dermata Therapeutics, you can compare the effects of market volatilities on Amylyx Pharmaceuticals and Dermata Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Amylyx Pharmaceuticals with a short position of Dermata Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Amylyx Pharmaceuticals and Dermata Therapeutics.

Diversification Opportunities for Amylyx Pharmaceuticals and Dermata Therapeutics

-0.53
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Amylyx and Dermata is -0.53. Overlapping area represents the amount of risk that can be diversified away by holding Amylyx Pharmaceuticals and Dermata Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dermata Therapeutics and Amylyx Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Amylyx Pharmaceuticals are associated (or correlated) with Dermata Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dermata Therapeutics has no effect on the direction of Amylyx Pharmaceuticals i.e., Amylyx Pharmaceuticals and Dermata Therapeutics go up and down completely randomly.

Pair Corralation between Amylyx Pharmaceuticals and Dermata Therapeutics

Given the investment horizon of 90 days Amylyx Pharmaceuticals is expected to generate 1.31 times more return on investment than Dermata Therapeutics. However, Amylyx Pharmaceuticals is 1.31 times more volatile than Dermata Therapeutics. It trades about 0.15 of its potential returns per unit of risk. Dermata Therapeutics is currently generating about -0.09 per unit of risk. If you would invest  515.00  in Amylyx Pharmaceuticals on May 4, 2025 and sell it today you would earn a total of  257.00  from holding Amylyx Pharmaceuticals or generate 49.9% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Amylyx Pharmaceuticals  vs.  Dermata Therapeutics

 Performance 
       Timeline  
Amylyx Pharmaceuticals 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Amylyx Pharmaceuticals are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating essential indicators, Amylyx Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.
Dermata Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Dermata Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in September 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Amylyx Pharmaceuticals and Dermata Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Amylyx Pharmaceuticals and Dermata Therapeutics

The main advantage of trading using opposite Amylyx Pharmaceuticals and Dermata Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Amylyx Pharmaceuticals position performs unexpectedly, Dermata Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will offset losses from the drop in Dermata Therapeutics' long position.
The idea behind Amylyx Pharmaceuticals and Dermata Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Complementary Tools

Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets